Cagrilintide in Vietnam

Cagrilintide is an investigational long-acting amylin analog peptide designed for obesity and metabolic research. It works by increasing satiety and slowing gastric emptying, leading to reduced food intake and significant weight loss potential.

Mimics amylin to regulate appetite and increase fullness.

Often combined with GLP-1 peptides for stronger weight loss effects.

Considered a next-generation peptide for metabolic and fat-loss protocols.

Scan to view COA

Key Aspects

Why Cagrilintide is gaining attention

These are the main areas Cagrilintide is being studied for.

Appetite suppression

Acts on amylin and calcitonin receptors to increase satiety and reduce food intake.

Weight loss potential

Clinical trials show strong weight-loss effects, especially when combined with GLP-1 peptides, with results exceeding many single-agent therapies.

Combination therapy

Often paired with semaglutide (CagriSema), combining amylin and GLP-1 pathways for enhanced metabolic results.

Further Details

How it works, usage, and important notes

Mechanism & usage

Mechanism: Mimics amylin, a hormone released with insulin that regulates satiety and slows gastric emptying.
Combination effect: Works synergistically with GLP-1 and GIP peptides for stronger appetite suppression.
Administration: Once-weekly subcutaneous injection.
Typical research dose: Studies commonly reference around 2.4 mg weekly.
Available sizes:
- 5mg
- 10mg

Side effects & status

Side effects: Nausea, vomiting, and diarrhea are the most commonly reported effects.
Status: Currently in Phase 3 clinical trials and not FDA-approved.
Trial results: Combination studies (CagriSema) have shown around 17%+ weight loss in shorter-term trials.
Warning: Unregulated or compounded versions may carry safety and quality risks.
Disclaimer: This information is for educational purposes only and does not constitute medical advice.

Common Stacks

Cagrilintide stacks and related peptides

Cagrilintide is most commonly combined with GLP-1-based peptides to enhance satiety and weight loss through complementary mechanisms.

Primary combinations

Cagrilintide + Semaglutide (CagriSema): A highly studied combination showing greater weight loss than semaglutide alone.
Cagrilintide + Retatrutide: Advanced metabolic stack targeting multiple appetite and energy pathways.

Stack considerations

Mechanism synergy: Combines satiety signaling (amylin) with GLP-1/GIP pathways.
Administration: Typically once-weekly injections.
Side effects: Gastrointestinal issues may increase when combining compounds.
Warning: FDA has raised concerns about unapproved compounded GLP-1-related drugs.
Important: Stacking should only be done under professional supervision.